Memorial Sloan Kettering Cancer Center-led researchers have identified a small molecule called gliocidin that kills ...

Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a ...

The physician and surgeon was diagnosed with glioblastoma in 2020 and went through treatment while pregnant with her son ...

The reversible transition between glioblastoma tumor-initiating cells, also known as glioma stem cells (GSCs), and differentiated glioma cells due to epigenetic modifications is one of the challenges ...

As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...

Shuttle Pharmaceuticals Holdings, Inc. recently disclosed in an 8-K filing to the Securities and Exchange Commission that the company has started enrolling patients and administering doses at the UVA ...

Scientists created a new therapeutic design for glioblastoma, the deadliest form of brain cancer. The lab engineered molecules called trispecifics that connect cancer-killing T cells with not just one ...

Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished ...

She was diagnosed with glioblastoma, an aggressive form of brain cancer, in 2020, and used her platform to talk about cancer ...

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...